Long
$kavl - worth paying attention to
KAVL has been having a sort of pre-news / event capitulation once a month since releasing revenues for the first time in april. that event appeared to have happened yesterday and with the quarter ending on july 31 we can expect news in the coming week, maybe two. also worth noting is after approaching the 50DMA KAVL tends to run.Fundamentals
Positive Earnings last quarter - $22M rev and $4M profit w/ 2 distribution channels
June / July
KAVL uplisted to the OTCQB and price increased from roughly $0.50 to 1.00News for this quarter not yet priced in:
1 Distribution channels have grown from 2 to 8
2 International Distribution to New Zealand and the UK
3 FDA approved product (1 of very few)
With increased distribution rev and earnings should at a minimum double.
otcmarkets.com/stock/KAVL/disclosure
Note
Earnings due out anytime. Retraced to the 50DMA last week and bounced hard as it has several time prior to news and earnings this year.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.